Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain.

MLA

Olry de Labry Lima, Antonio, et al. “Cost-Effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain.” Revista Espanola de Cardiologia (English Ed.), vol. 71, no. 12, Dec. 2018, pp. 1027–35. EBSCOhost, https://doi.org/10.1016/j.rec.2018.05.003.

APA

Olry de Labry Lima, A., Gimeno Ballester, V., Sierra Sánchez, J. F., Matas Hoces, A., González-Outón, J., & Alegre Del Rey, E. J. (2018). Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain. Revista Espanola de Cardiologia (English Ed.), 71(12), 1027–1035. https://doi.org/10.1016/j.rec.2018.05.003

Chicago

Olry de Labry Lima, Antonio, Vicente Gimeno Ballester, Jesús Francisco Sierra Sánchez, Antonio Matas Hoces, Julio González-Outón, and Emilio Jesús Alegre Del Rey. 2018. “Cost-Effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain.” Revista Espanola de Cardiologia (English Ed.) 71 (12): 1027–35. doi:10.1016/j.rec.2018.05.003.